Related Experiment Video
Updated: Aug 4, 2025
Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
5'-CMP and 5'-UMP alleviate dexamethasone-induced muscular atrophy in C2C12 myotubes
Kosuke Nakagawara1, Chieri Takeuchi2, Kazuya Ishige1
1Biochemicals Division, YAMASA Corporation, 2-10-1 Araoicho, Choshi, 288-0056, Japan.
Abstract:
Atrogin-1 and muscle RING finger 1 (MuRF1) are ubiquitin ligases specifically expressed during skeletal muscle atrophy and mediate muscle protein degradation. In contrast, PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α), which is a master regulator of mitochondrial biosynthesis, protects skeletal muscle from atrophy. Pyrimidine nucleoside 5'-monophosphates, such as cytidine 5'-monophosphate (5'-CMP) and uridine 5'-monophosphate (5'-UMP), induce PGC-1α expression and promote myotube formation in mouse C2C12 cells. In this study, we determined the effect of 5'-CMP and 5'-UMP on muscular atrophy in C2C12 myotube cells. 5'-UMP decreased Atrogin-1 and MuRF1 mRNA levels that were upregulated by dexamethasone treatment. 5'-CMP and 5'-UMP ameliorated dexamethasone-mediated atrophy in C2C12 myotubes. Furthermore, the combination of 5'-CMP and 5'-UMP further alleviated dexamethasone-mediated atrophy. In addition, cytidine and uridine, the precursors of 5'-CMP and 5'-UMP, markedly ameliorated dexamethasone-mediated atrophy. Considering nucleotide metabolism and absorption, the active metabolites underlying the observed effects of 5'-CMP and 5'-UMP appear to be cytidine and uridine. Our results indicate that 5'-CMP alleviates muscle atrophy by activating PGC-1α and differentiation, and 5'-UMP alleviates muscle atrophy by suppressing the activation of the myolytic system, whereas the combined use of both enhances the muscle atrophy inhibitory effect. 5'-CMP and 5'-UMP may be an effective and safe treatment for muscular atrophy.
Insights
Cytidine 5'-monophosphate (5'-CMP) and uridine 5'-monophosphate (5'-UMP) alleviate muscle atrophy by affecting key proteins and pathways. Their precursors, cytidine and uridine, also show protective effects, suggesting a potential therapeutic strategy for muscle wasting.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Skeletal muscle atrophy involves ubiquitin ligases Atrogin-1 and MuRF1, which mediate protein degradation.
- Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is crucial for mitochondrial biogenesis and muscle protection.
- Pyrimidine nucleoside 5'-monophosphates, like 5 eal-CMP and 5 eal-UMP, can influence PGC-1α expression and myotube formation.
Purpose of the Study:
- To investigate the effects of 5 eal-CMP and 5 eal-UMP on dexamethasone-induced muscle atrophy in C2C12 myotubes.
- To elucidate the mechanisms by which these nucleotides modulate atrophy-related gene expression and cellular processes.
Main Methods:
- Treatment of mouse C2C12 myotubes with dexamethasone to induce atrophy.
- Administration of 5 eal-CMP, 5 eal-UMP, cytidine, and uridine to assess their protective effects.
- Measurement of Atrogin-1 and MuRF1 mRNA levels.
- Evaluation of PGC-1α activation and myotube differentiation.
Main Results:
- 5 eal-UMP significantly decreased Atrogin-1 and MuRF1 mRNA levels upregulated by dexamethasone.
- Both 5 eal-CMP and 5 eal-UMP ameliorated dexamethasone-mediated atrophy in C2C12 myotubes.
- The combination of 5 eal-CMP and 5 eal-UMP, as well as their precursors cytidine and uridine, demonstrated enhanced protective effects against muscle atrophy.
Conclusions:
- 5 eal-CMP alleviates muscle atrophy by promoting PGC-1α activation and differentiation.
- 5 eal-UMP combats muscle atrophy by suppressing the myolytic system.
- Combined administration of 5 eal-CMP and 5 eal-UMP offers synergistic benefits, suggesting their potential as safe and effective treatments for muscular atrophy.
More Related Videos
12:19Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin shRNA
Published on: February 12, 2020
06:52Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
